FibroGen to Participate in Upcoming Investor Conferences
07 mai 2024 07h00 HE
|
FibroGen, Inc.
SAN FRANCISCO, May 07, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the company’s management will participate in the following investor conferences: Bank of America...
FibroGen Reports First Quarter 2024 Financial Results
06 mai 2024 16h02 HE
|
FibroGen, Inc.
Topline data from the Pancreatic Cancer Action Network (PanCAN) Precision PromiseSM Phase 2/3 study in metastatic pancreatic cancer anticipated in mid-2024Topline data from LAPIS Phase 3 study in...
FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results
26 févr. 2024 16h06 HE
|
FibroGen, Inc.
• Topline data from two pivotal pamrevlumab pancreatic cancer trials anticipated in 2Q 2024 • Additional data from Phase 1 monotherapy study of FG-3246 in metastatic castration-resistant prostate...
FibroGen Reports Second Quarter 2023 Financial Results
07 août 2023 16h01 HE
|
FibroGen, Inc.
Topline data from three late-stage pamrevlumab trials expected through 1H 2024, including the Pancreatic Cancer Action Network (PanCAN) Precision PromiseSM Phase 2/3 study in metastatic pancreatic...
FibroGen Announces Completion of Patient Enrollment in MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Lower Risk Transfusion-Dependent Myelodysplastic Syndromes (MDS)
26 août 2022 07h00 HE
|
FibroGen, Inc.
- 141 MDS Patients Enrolled -- Topline Data Anticipated 1H:2023 - SAN FRANCISCO, Aug. 26, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced completion of patient enrollment for...
FibroGen Shareholder Alert: Shareholder Class Action Survives in Part Motion to Dismiss; Should Management be Held Accountable for Shareholder Losses? Contact Johnson Fistel, Globally-Recognized Law Firm
19 juil. 2022 13h33 HE
|
Johnson Fistel, LLP
SAN DIEGO, July 19, 2022 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP is investigating potential claims on behalf of FibroGen, Inc. (NASDAQ: FGEN) against certain of its officers and directors. If you...
FibroGen to Present at Jefferies Healthcare Conference
26 mai 2022 07h00 HE
|
FibroGen, Inc.
SAN FRANCISCO, May 26, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the Jefferies...
FibroGen Reports First Quarter 2022 Financial Results
09 mai 2022 16h01 HE
|
FibroGen, Inc.
Completed enrollment in ZEPHYRUS-1 Phase 3 study of pamrevlumab in idiopathic pulmonary fibrosis1Q 2022 revenue of $60.8M, growth of 58% vs. 1Q 2021Significant roxadustat volume growth in China in...
FibroGen to Present at SVB Leerink 11th Annual Global Healthcare Conference
04 févr. 2022 07h00 HE
|
FibroGen, Inc.
SAN FRANCISCO, Feb. 04, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the SVB Leerink...
FibroGen to Present at H.C. Wainwright Bioconnect Virtual Conference
04 janv. 2022 07h00 HE
|
FibroGen, Inc.
SAN FRANCISCO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the H.C....